Comparison of everolimus with calcineurin inhibitors in maintenance immunosuppression
International Journal of Artificial Organs, cilt.49, sa.4, ss.235-240, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 49 Sayı: 4
- Basım Tarihi: 2026
- Doi Numarası: 10.1177/03913988261429909
- Dergi Adı: International Journal of Artificial Organs
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, Compendex, EMBASE, MEDLINE, Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Sayfa Sayıları: ss.235-240
- Anahtar Kelimeler: Heart transplantation, & imath;mmunosuppressive therapy, calcineurin inhibitors, renal dysfunction
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: The conventional triple immunosuppressive regimen administered following heart transplantation typically comprises a calcineurin inhibitor, an antiproliferative agent, and corticosteroids. Everolimus has emerged as a viable alternative to calcineurin inhibitors. This study aims to evaluate the immunosuppressive efficacy and adverse effect profile of everolimus when introduced after the first post-transplant year, in comparison to continued calcineurin inhibitor therapy. Methods: A retrospective analysis was conducted on 90 heart transplant recipients under regular follow up. Patients were categorized into two groups: those who maintained calcineurin inhibitor therapy beyond the first year post-transplant (n = 45), and those who transitioned to everolimus after the first year (n = 45). The groups were compared in terms of rejection incidence and side effects. Results: Following the treatment modification, the everolimus group showed a significant improvement in serum urea and creatinine levels (p < 0.05). Rejection rates after the first year were found to be similar between the two groups. Conclusion: Everolimus provides effective immunosuppression with a lower rate of side effects.It demonstrates a favorable impact on renal function without increasing the risk of rejection.The first year may be recommended as the optimal timing, considering both safe wound healing and the risk of rejection.